Immunomedics to Report Progress With Novel DNL Agents Targeting Solid Tumors at Cancer Conference

MORRIS PLAINS, N.J., March 26, 2012 (GLOBE NEWSWIRE) -- Immunomedics, Inc. IMMU, a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that six posters will be presented at the 2012 Annual Meeting of the American Association for Cancer Research (AACR) to be held in Chicago, IL, from March 31 – April 4, 2012.

Three of the 6 presentations will be on novel multivalent/multifunctional fusion proteins created by the Company's patented Dock-and-Lock (DNL) conjugation technology. They include bispecific hexavalent antibodies, as well as toxin or cytokine conjugates of antibodies, that bind to receptors found on many human solid tumors.

The schedule and meeting places for the poster sessions, together with the abstract number, poster section and poster board numbers, are listed below:

• "Pretargeted radioimmunotherapy of an anti-CEA bispecific antibody and ¹⁷⁷Lu-labeled peptide: a phase I study in patients with advanced colorectal cancer" [Abstract No. 1755, Session Title: Clinical Trials in Progress, Monday, April 2, 8:00 a.m. – 12:00 p.m., Poster Section 27, Poster Board Number 16, McCormick Place West (Hall F)]
   
• "The in vitro effects of immobilized epratuzumab, a non-blocking anti-CD22 humanized monoclonal antibody, on malignant B cells" [Abstract No. 2523, Session Title: Antibody Therapeutics, Monday, April 2, 1:00 p.m. – 5:00 p.m., Poster Section 19, Poster Board Number 18, McCormick Place West (Hall F)]
   
• "Optimal cleavable linker for antibody-SN-38 conjugates for cancer therapy: Impact of linker's stability on efficacy" [Abstract No. 2526, Session Title: Antibody Therapeutics, Monday, April 2, 1:00 p.m. – 5:00 p.m., Poster Section 19, Poster Board Number 21, McCormick Place West (Hall F)]
   
• "Bispecific, hexavalent antibodies (HexAbs) targeting IGF-1R and either Trop-2 or CEACAM6 inhibit anchorage-independent growth and invasion of antigen-expressing breast and pancreatic cancer cell lines in vitro" [Abstract No. 2727, Session Title: Biological Therapy Based on Viruses, Antibodies, or Metformin, Monday, April 2, 1:00 p.m. – 5:00 p.m.,  Poster Section 28, Poster Board Number 16, McCormick Place West (Hall F)]
   
• "The anti-tumor effects of two novel multivalent/multifunctional agents derived from hR1, a humanized anti-IGF-1R mAb, are enhanced in renal cell carcinoma and synergistic with an mTOR inhibitor" [Abstract No. 4402, Session Title: Immunomodulation and Combinatorial Immunotherapy, Tuesday, April 3, 1:00 p.m. – 5:00 p.m., Poster Section 19, Poster Board Number 19, McCormick Place West (Hall F)]
   
• "Novel immunoRNases comprising multiple copies of ranpirnase display potent cytotoxicity in human breast cancer cell lines expressing Trop-2" [Abstract No. 4636, Session Title: Antibody and Microenvironmental Therapies, Tuesday, April 3, 1:00 p.m. – 5:00 p.m., Poster Section 28, Poster Board Number 17, McCormick Place West (Hall F)]

About Immunomedics

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins, in each case to create highly targeted agents. Using these technologies, we have built a pipeline of therapeutic product candidates that utilize several different mechanisms of action. We also have a majority ownership in IBC Pharmaceuticals, Inc., which is developing a novel Dock-and-Lock (DNL) methodology with us for making fusion proteins and multifunctional antibodies, and a new method of delivering imaging and therapeutic agents selectively to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting methods. We believe that our portfolio of intellectual property, which includes approximately 190 patents issued in the United States and more than 400 foreign patents, protects our product candidates and technologies. For additional information on us, please visit our website at www.immunomedics.com. The information on our website does not, however, form a part of this press release.

This release, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein. Factors that could cause such differences include, but are not limited to, risks associated with any cash payment that the Company might receive in connection with a sublicense involving a third party and UCB, which is not within the Company's control, new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.